Searchable abstracts of presentations at key conferences on calcified tissues

ba0005p208 | Cell biology: Osteocytes, mechanobiology | ECTS2016

Transgene expression by Dmp1 promoter fragments occurs in various organs

Saito Hiroaki , Taipaleenmaki Hanna , Al-Jazzar Ahmed , Gasser Andreas , Javaheri Behzad , Scudamore Cheryl , Bellido Teresita , Pitsillides Andrew A , Hesse Eric

Analysis of osteocyte function often uses promoter elements of osteocyte-specific genes i.e. SOST or Dentin-matrix-protein 1 (Dmp1) to overexpress genes or the Cre-recombinase for conditional deletion studies. However, evidence suggests that these promoters may not be osteocyte-specific, which would be critical for subsequent data interpretation. To investigate the selectivity of supposedly osteocyte-specific in vivo models, we crossed the 8kb-Dmp1-Cre mice (i) with A...

ba0005p490 | Steroid hormones and receptors | ECTS2016

Phosphorylation of S122 in ERα is important for the skeletal response to estrogen treatment

Gustafsson Karin , Farman Helen , Lionikaite Vikte , Wu Jianyao , Henning Petra , Andersson Annica , Islander Ulrika , Bernardi Angelina , Windahl Sara , Skrtic Sofia , Sjogren Klara , Koskela Antti , Tuukkanen Juha , Krust Andree , Chambon Pierre , Ohlsson Claes , Lagerquist Marie

It is well established that estrogen, mainly via estrogen receptor alpha (ERα), has positive effects on bone, but estrogen is not considered as a treatment option against osteoporosis due to negative side-effects in other tissues. ERα is widely subjected to posttranslational modifications (PTMs), which can affect cellular responses to estrogen in a tissue specific manner by influencing the function of ERα and its interactions with other proteins. The in vivo...

ba0002p173 | (1) | ICCBH2013

Vitamin D prescription: a review of British National Formulary for children recommendations, and a proposal

Kouklinos Andreas , Lim Julian , Jacobs Benjamin

Aims: To review changes in the advice regarding vitamin D deficiency in the UK and compare these with other national guidance.Methods: All Vitamin D guidance in the Royal College of Paediatrics and Child Health 2003 guide (Medicines for Children) and in the eight editions since the British National Formulary for Children (BNFc) was first published in 2005 was reviewed.Results: Dosage and indications of prevalence are shown in the T...

ba0003pp304 | Osteoporosis: treatment | ECTS2014

Activin decoy receptor (IIA) ameliorates immobilisation induced loss of bone and muscle mass in mice

Lodberg Andreas , Thomsen Jesper Skovhus , Bruel Annemarie

Activin is a known physiologic regulator of bone metabolism. Ovariectomy-induced osteopenia has been shown to be attenuated by injection of the activin type IIA decoy receptor (ActRIIA-Fc). However, immobilization-induced osteopenia is driven by different pathways than ovariectomy-induced osteopenia, and the role of activin in immobilization-induced osteopenia has not yet been elucidated.The purpose of the study was to investigate the possible attenuatio...

ba0003pp312 | Osteoporosis: treatment | ECTS2014

Farnesylpyrophosphate synthase rs2297480 polymorphism and the response to the zoledronic acid in the treatment of postmenopausal osteoporosis

Yureneva Svetlana , Yakushevskaya Oksana , Donnikov Andrey , Kuznetzov Sergey , Mullambaeva Svetlana , Alekseeva Marina , Trophymov Dmitry , Ivanetz Tatyana , Sukhikh Gennady

Research design and methods: A characterisation of 225 European (Russian) osteoporotic postmenopausal women, treated for 2 years with amino-bisphosphonate zoledronic acid (zol), with respect to the adenosine/cytosine (A/C) rs2297480 farnesyl pyrophosphate synthase (FDPS) gene polymorphism, was carried out by PCR-based enzymatic digestion and quantitative PCR allelic discrimination on genomic DNA extracted from blood leukocytes. The association between these polymorphism genoty...

ba0001pp364 | Osteoporosis: pathophysiology and epidemiology | ECTS2013

Osteoporosis an independent predictor of mortality in hip fracture patients

Diamantopoulos Andreas P , Hoff Mari , Hochberg Marc , Haugeberg Glenn

Introduction: Mortality after hip fracture is increased. However, only a few studies have explored for predictors beyond gender and age. Thus our aim was to study risk factors associated with increased mortality in hip fracture patients.Methods: Hip fracture patients (>50 years) admitted to a county hospital in 2004–2005 were consecutively invited for assessment at the hospital osteoporosis centre. A broad spectre of data was collected. Standard...

ba0002p171 | (1) | ICCBH2013

Vitamin D levels and signs of metabolic bone disease in adolescents with idiopathic scoliosis

Adodra Annika , Kouklinos Andreas , Julies Priscilla , Shaw Mathew , Jacobs Benjamin

Objective: Biochemical assessment of teenage patients with adolescent idiopathic scoliosis (AIS).Methods: Blood sampling from 120 patients with AIS aged 12–17 years. The patients all had significant scoliosis and blood samples were taken a few days or weeks before they underwent scoliosis surgery. Serum 25-hydroxy-vitamin D (25-OHD), calcium, phosphate, alkaline phosphatase and parathyroid hormone (PTH) were measured. Patients with a 25-OHD level be...

ba0003pp37 | Bone biomechanics and quality | ECTS2014

Bone matrix mineralization after sclerostin antibody treatment in a mouse model of osteogenesis imperfecta

Roschger Andreas , Roschger Paul , Kneissel Michaela , Rauch Frank

Children with osteogenesis imperfecta (OI) still suffer from frequent fractures, despite bisphosphonate treatment. Thus new therapeutic approaches are needed. Sclerostin is a protein that is thought to inhibit bone formation. Treatment with sclerostin antibodies (SclAB) increases bone mass in animal models and in clinical trials and may be a rational therapy for OI as well.Transgenic (TgOI) Col1a1Jrt/+ mice were gene...